Light therapies to improve sleep in intrinsic circadian rhythm sleep disorders and neuro-psychiatric illness: A systematic review and meta-analysis by Faulkner, Sophie M. et al.
lable at ScienceDirect
Sleep Medicine Reviews 46 (2019) 108e123Contents lists avaiSleep Medicine Reviews
journal homepage: www.elsevier .com/locate/smrvCLINICAL REVIEWLight therapies to improve sleep in intrinsic circadian rhythm sleep
disorders and neuro-psychiatric illness: A systematic review and
meta-analysis
Sophie M. Faulkner a, b, *, Penny E. Bee a, Nicholas Meyer c, Derk-Jan Dijk d,
Richard J. Drake a, b
a School of Health Sciences, University of Manchester, Manchester, UK
b Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK
c Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
d Surrey Sleep Research Centre, Surrey Clinical Research Centre, University of Surrey, Guildford, Surrey, UKa r t i c l e i n f o
Article history:
Received 9 November 2018
Received in revised form
2 April 2019
Accepted 23 April 2019
Available online 30 April 2019
Keywords:
Bright light treatment
Dark treatment
Dawn simulation
Circadian rhythm sleep disorders
Co-morbid insomnia
Mental illness
Dementia
Delayed sleep phase disorder
Affective disorders
Psychosis* Corresponding author. Faculty of Biology, Medicin
of Manchester, Jean McFarlane Building, Oxford Rd, M
E-mail address: sophie.faulkner@manchester.ac.uk
https://doi.org/10.1016/j.smrv.2019.04.012
1087-0792/© 2019 Published by Elsevier Ltd.s u m m a r y
Circadian dysregulation causes sleep disturbance and impacts quality of life and functioning. Some in-
terventions target circadian entrainment through modifying light exposure, but existing reviews of light
interventions for sleep improvement include few studies in psychiatric populations. We examined effect
of light interventions on sleep quality, duration and timing, and effect moderators. We included
controlled studies in intrinsic circadian rhythm disorders (such as advanced or delayed sleep) and in
neuropsychiatric disorders with assumed high prevalence of circadian dysregulation (such as affective
and psychotic disorders). Articles were identiﬁed through database searching: 40 studies reporting 49
relevant intervention comparisons met inclusion criteria. Meta-analysis showed improvements in sleep
continuity (ES ¼ 0.23, p ¼ 0.000), self-reported sleep disturbance (ES ¼ 0.32, p ¼ 0.014), and
advancement of delayed sleep timing (ES ¼ 0.34, p ¼ 0.010). Although the small number of studies
limited meta-regression, evening light avoidance was associated with greater increase in total sleep time.
Effects of light on sleep and circadian outcomes have received limited attention in studies in psychiatric
disorders, but results were promising in these groups. These ﬁndings invite further reﬁnement and
testing of light interventions to improve sleep in psychiatric disorders, with improved assessment and
speciﬁcation of problems, and the development and implementation of light schedule interventions for
delayed sleep.
© 2019 Published by Elsevier Ltd.Introduction
Circadian rhythms exert a strong inﬂuence on sleep propensity,
alertness and performance, modulating these each day [1]. Circa-
dian rhythms are entrained to the external day-night cycle by
environmental cues, of which the light-dark cycle is by far the
strongest inﬂuence [2].When circadian rhythms arewell entrained,
the suprachiasmatic nucleus (SCN) oscillates in time with the
external day-night cycle, and all other bodily tissues and organs are
synchronised by the SCN's rhythmic signal. Circadian dysregulation
has been connected to various negative physical and mental healthe and Health, The University
anchester, M13 9PL, UK.
(S.M. Faulkner).consequences, and of course, to poor sleep [3]. As circadian rhythms
are known to be entrained by light exposure, interventions that
modify light exposure patterns to reduce sleep disturbance have
strong theoretical support. Light and darkness also inﬂuence sleep
and arousal processes more acutely, through ‘direct’, non-circadian
pathways, which may contribute toward therapeutic effects [4].
In circadian rhythm sleep disorders (CRSDs) such as delayed
sleep phase disorder (DSPD) or advanced sleep phase disorder
(ASPD), interventions may aim to normalise timing of sleep. In-
terventions may equally aim to improve sleep quality or duration
by improving the synchronisation between circadian phase and
sleep-wake timing where these are out of phase [5]. Interventions
may aim to increase the amplitude of the SCN rhythm, which can
become reduced in older age and in neurodegenerative disorders
[6]. Symptoms of circadian dysregulation also frequently occur in
Glossary
Suprachiasmatic nucleus (SCN) the brain's internal master
clock, cells in the SCN
oscillate with a period of
approximately 24hr, and are
entrained to external time by
environmental cues.
Zeitgeber from German “time-giver”; environmental cues
which entrain circadian rhythms; light is the
strongest zeitgeber for entraining circadian
rhythms.
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sleep wake disorder (ISWD) is common in dementia [7]. ‘Free-
running’ rhythms (non 24hr sleep wake disorder) most commonly
occur due to eye or optic nerve damage. Non 24hr rhythms can be
observed in time-cue free environments in sighted participants [8],
but occur under free-living conditions in sighted people with
schizophrenia [9] and rapid-cycling bipolar disorder [10].
Circadian dysregulation impacts negatively on quality of life, on
occupational and social engagement [11e13], and on cognitive
functioning [14]. Although causality is challenging to investigate,
evidence suggests circadian dysregulation and poor sleep exacer-
bate psychiatric symptoms [15e17]. Circadian dysregulation very
often precedes other symptoms, and some evidence suggests a
causal role in development of illness [18,19]. There is much hope
that treating circadian dysregulation and reducing sleep distur-
bance might improve functioning and reduce suffering in a range of
conditions. Indeed, some studies which reduced insomnia via
psychological intervention, reported a reduction in psychiatric
symptoms [20e22]; these effects have been shown to be mediated
by reductions in sleep disturbance [20].
Historically sleep problems have been neglected in groups with
neuropsychiatric disorders due to diagnostic overshadowing [23],
and assumptions that sleep problems are purely secondary to
psychiatric symptoms. Unfortunately sleep problems often persist
even if affective or psychotic symptoms are well-controlled [24,25].
There is increasing recognition that sleep problems require inde-
pendent attention irrespective of co-morbid conditions. In accor-
dance with this the ‘primary’/‘secondary’ insomnia distinction was
removed from DSM-5 and ICSD-3 [26]. Circadian dysregulation
disorder deﬁnitions have not been similarly modiﬁed; the ICSD-3
stipulates for diagnosis of CRSD the sleep disturbance must not
be “better explained” by another medical, neurologic or mental
disorder. Further, it contains no category for CRSD secondary to
another disorder [27]. Studies which examine circadian dysregu-
lation in samples with neuropsychiatric disorders ﬁnd high prev-
alence of patterns similar to ASPD, DSPD, ISWD and non-24hr
[6,9,24], but usually CRSD terminology is not applied.
Previous meta-analyses of studies of light treatment for sleep
improvement in CRSD (without co-morbidity) and in dementia
were inconclusive, and limited by small participant and trial
numbers [28,29]. Despite the high levels of circadian dysregulation
symptoms in populations with severe mental illness, no meta-
analysis has yet included studies in these groups. In the meta-
analysis by Van Maanen et al. (2016) [30] broad inclusion criteria
were used, including any reported or diagnosed sleep disorder or
complaint. The authors identiﬁed studies in groups as diverse as
renal patients, brain injury, and mid-winter insomnia in the sub-
arctic, yet no studies targeting sleep in samples with co-morbid
mental illness which met inclusion criteria were found.Evidence syntheses of the effects of light in seasonal and non-
seasonal mood disorders have shown effects on improvement in
mood [31,32], but the effects on sleep are less well understood.
This review presents a synthesis of the effects of light schedule
interventions on circadian rest-activity patterns and sleep, across
dementia, CRSD, and psychotic, affective and personality disorders.
Acknowledging the lack of measurement of circadian dysregulation
and application of CRSD terminology in existing research in psy-
chiatric disorders, our inclusion criteria are operationalised spe-
ciﬁcally to ensure studies in these groups are not excluded.
Our aims are: 1) To examine the effect of interventions altering
light exposure patterns on sleep and rest-activity parameters, in
populations diagnosed with, or at risk of, circadian dysregulation.
2) To examine predictors of effect size.
Methods
The protocol for this review was prospectively published on
Prospero, and is available at: http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID¼CRD42017072387. For changes
from protocol see Supplement S1.
Search, screening and inclusion
Systematic searches were performed using keywords and sub-
ject headings in MEDLINE, Embase, PsycInfo, and AMED (via Ovid),
and CINAHL (via EBSCO). Searches were run in August 2017, from
database inception. Truncation (*), wildcards, and the (adj) adja-
cent operator were used to capture terminology variants.
Searches were limited to human studies, and a trial ﬁlter was
applied; 10% of articles excluded by the trial ﬁlter were screened to
conﬁrm no relevant studies were being ﬁltered. Database searches
were supplemented by reference checking relevant reviews and
contacting key authors in the ﬁeld. Only peer-reviewed publica-
tions of primary research were included. For an example search
strategy see Supplement S2.
We included populations with intrinsic CRSDs, and those with
other conditions strongly associated with circadian dysregulation.
We identiﬁed and speciﬁed a list of conditions a priori based on the
background literature; amongst them were dementia, psychotic
disorders and affective disorders (see Tables 1 and S3).
During screening we encountered studies where participants
were not formally diagnosed with DSPD or ASPD, but where in-
clusion criteria speciﬁed suggested that most participants had
DSPD or ASPD. After discussion we included these studies and
planned a sensitivity analysis on the effect of their removal. We
excluded groups at-risk of (not currently presenting with) mental
disorders, ‘extrinsic’ CRSDs, speciﬁcally jet-lag disorder and shift
work disorder, and problems occurring due to very unusual light
environments (e.g., space ﬂight, arctic winter).
Results were de-duplicated and screened; one third of results
were independently screened by another researcher. Authors of
relevant conference abstracts were contacted to seek publications.
Potentially relevant studies were assessed for eligibility using the
full text. All those where there was ambiguity were assessed by
another researcher. An additional 10% of randomly selected full
texts were independently assessed by another researcher to check
consistency in application of the inclusion criteria. After familiar-
isation we found inconsistency only between categories “include”/
“unsure” and “exclude”/“unsure” – not between “include/
“exclude”, thereforewewere satisﬁed that all relevant studies were
being identiﬁed. Uncertainty was resolved through discussion, and
consulting a third researcher where needed. Where multiple pa-
pers reported on the same study all were included and data were
combined.
Table 1
Inclusion criteria.
Study type Intervention study (not observational and correlational studies)
Exclude: case studies (<5 people)
Population Intrinsic CRSD (DSPD, ASPD, ISWD or Non-24hr)a
OR
Psychiatric or neurodegenerative disease with high levels of circadian dysregulation: dementia, psychotic disorders, personality disorder, affective
disorders (bi-polar or unipolar, seasonal or non-seasonal)
AND
Over 70% of the sample meet the above criteria, or subgroups reported
Adults or adolescents (over 13)
Intervention Interventions altering light exposure (amount, timing, or spectral qualities) as a core (not optional) component, with primary or secondary aim of
improving sleep.
Examples: light boxes, light visors, dark treatment, amber glasses, increasing daylight exposure, increasing or decreasing indoor lighting.
Comparison Control group without the light/dark intervention
Outcome Self-reported, clinician reported, or objectively measured sleep or rest-activity variables (Sleep onset latency, maintenance, quality, depth, timing,
duration, rest-activity patterns)
a CRSD ¼ circadian rhythm sleep disorder, DSPD ¼ delayed sleep phase disorder, ASPD ¼ advanced sleep phase disorder, ISWD irregular sleep wake disorder, Non-
24hr ¼ non-24hr sleep wake phase disorder, SCN ¼ suprachiasmatic nucleus.|
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Population, setting, intervention and outcomes data were
extracted and cross-checked by another researcher. Mean, standard
deviation (SD) and sample size were extracted, or where required
calculated (from conﬁdence intervals (CIs) and standard errors
(SEs)), or requested from authors. Where outcome measures were
scaled in the opposite direction (e.g., higher ¼ better,
higher ¼ worse) effect sizes were reversed. Clock times (hours,
minutes) were converted to decimal hours or total minutes.
Risk of bias assessment
Methodological quality in controlled studies was appraised
during data-extraction using the Cochrane risk of bias tool.
Participant blinding is a pervasive difﬁculty in light/dark treatment
(interventions are by nature perceptible) and this affected overall
risk of bias assessments across studies. It was therefore decided to
use gradations of ‘low/medium/high’, to capture more information
than ‘low/high’ quality ratings. Studies were independently
assessed by a second researcher, discrepancies were resolved
through discussion.
Analysis
There are various sleep outcomes, many of which are dissimilar,
and therefore not amenable to pooling. The relevance of outcomes
in each group was based upon the known complaints of that
population and relevancewas noted a-priori to guide synthesis (see
Table S4).
To reduce risk of bias in outcome extraction, a hierarchy of
outcome measures for each construct was determined a priori, in
casemultiplemeasures were reported (e.g., TSTactigraphy and self-
report), so the preferred measure for that construct was pre-
determined (see Table S5).
Where studies included multiple relevant comparisons (for
instance morning light/afternoon light/placebo) each was included
individually, as differences in effects depending on intervention
features were of interest. To avoid double counting the control
group was split accordingly [33].
Meta-analyses and meta-regressions were run in Stata 14.
Standardisedmean differences (SMDs) were used due to inclusion of
multiple outcome measures, the random effects model was used to
allow for heterogeneity [34]. Meta-regression covariates were plan-
ned in advance. To avoid applying meta-regression with too few
trials [35] we set a lower limit of 10 comparisons. Covariates were
tabulated and visually inspected for collinearity and confounding toavoid misinterpretation of associations (e.g., if only studies in certain
diagnoses used afternoon light, population effects and intervention
effects cannot be separated). We did not run meta-regressions for
participant characteristics for which we had only a study mean, such
as age or mean baseline sleep quality, because without individual
patient data results may be misleading [35].
The following sensitivity analyses were run for each meta-
analysis:
1) Removing and examining any striking outliers
2) Removing studies at high risk of bias
3) Removing studies with neuropsychiatric diagnosis but no sleep
inclusion criteria.
4) Removing studies where diagnosis was assumed not formally
assessedSub-group analyses and differences in outcomes between
populations
It was our assumption on embarking on this review that there is
some commonality in mechanisms of sleep disturbance between
groups and therefore that there may be commonality in interven-
tion effects. Research in animal models and from genetic studies
suggests the mechanisms causing circadian dysregulation may be
similar across diagnostic groups [36,37]. Although our primary aim
was to examine effects across diagnostic groups, we have examined
sub-group differences [38]. We examined differences ﬁrst using
overall tests for heterogeneity between sub-groups for each meta-
analysis. We then examined sub-grouped forest plots and for those
where CIs did not overlap [33] we examined differences statistically
using the method described by Bornstein et al. [39].
Results
Search results
3319 unique results were returned, resulting in 320 potentially
relevant studies for which full-text was retrieved and assessed for
eligibility. 48 articles reporting on 40 studies met inclusion criteria.
Fig. 1 shows the ﬂow of articles through search and screening.
Study characteristics
There were 40 controlled studies reporting on 49 relevant
intervention comparisons (see Table 2). Studies in non-dementia
populations were conducted in participant's own homes, with the
exception of ﬁve inpatient studies [40e44]. Studies in dementia
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residences [45e48]. Themost commonly used interventionwas the
light box, followed by bright indoor light, outdoor light, or light
from a combination of sources. Light visors, dawn simulation, and
light avoidance were infrequently used. Many interventions were
single component. The most common additional components were
sleep schedule recommendations and sleep hygiene advice. Some
studies combined morning light exposure and evening light
avoidance. A small minority of studies combined light exposure
with exogenous melatonin [49,50], cognitive behavioural therapy
for insomnia (CBT-i) [40,51] or wake therapy [44]. Many in-
terventions did not describe including any maintenance advice or
treatment.
Population groupings were decided after data-extraction and
before analysis. The two studies in seasonal affective disorder (SAD)
both included hypersomnia, hence the category “SAD with hyper-
somnia”. Certain outcomes and measurement methods were more
common within certain diagnostic groups, for instance actigraphy
was most commonly used in dementia (Table S6 summarises out-
comes and measurement methods per study).
Risk of bias assessment
Many studies attempted participant blinding, but difﬁculties
were understandably common. To counter this some studies
assessed the participants' intervention expectations to determine
whether this accounted for outcomes. Rates of attritionwere highly
variable. Allocation methods were sometimes unclearly reported
(see Table S7).
Publication bias
Funnels plots were generated for each analysis. None appeared
skewed [52] and statistical testing suggested no publication biasFig. 1. PRISMA ﬂow diagram for search, screening and inclusion. *Includes
controlled trials with the wrong comparison, e.g., both groups gave the same light
exposure and modiﬁed another component.[53]. However, due to the small number of studies and limited
variation in trial size for many analyses, it is difﬁcult to accurately
interpret these plots and tests.
Outcomes
The effect of intervention compared to control condition was
statistically signiﬁcant for six outcomes; all in the desirable direc-
tion (see Table 3). Effects on sleep timing (in DSPD), self-reported
sleep disturbance, and sleep continuity disruption were robust to
all sensitivity analyses. Effects on sleep onset latency (SOL), total
sleep time (TST), and sleep quality were statistically signiﬁcant in
the main analysis but not in all sensitivity analyses (see
supplements S8eS20 for additional forest plots and S21 for sensi-
tivity analyses).
Delaying sleep timing in advanced sleep phase disorder (ASPD)
Samples were middle aged or older, and community based (see
Table 2). There were few studies and samples were small. All in-
terventions gave evening light or light during early sleep, none
restricted morning light. Effects were homogeneous. All studies
measured the ﬁrst-choice outcome e rise time. The pooled effect
was non-signiﬁcant, and in the wrong direction (toward even
earlier sleep) (effect size (ES) ¼ -0.15, p ¼ 0.602). To examine if this
suggested harm, we made post hoc examination of baseline
imbalance and pre-post effect. Intervention groups indeed had
earlier average rise time at baseline which persisted after inter-
vention, and there was no signiﬁcant pre-post effect in either di-
rection in the intervention group (ES ¼ 0.32, p ¼ 0.111).
Advancing sleep timing in delayed sleep phase disorder (DSPD)
All studies in DSPD measured sleep timing. Samples in DSPD
were young and community based, exclusion of co-morbidities
varied widely. All interventions increased light exposure in the
morning, and three involved some instruction to avoid or reduce
evening light exposure. Effects were homogeneous (c2 ¼ 6.00
(d.f. ¼ 8), p ¼ 0.648, I2 ¼ 0.0%), with the exception of Langevin et al.
(2014) [63] which was an extreme outlier. This study was small
(n¼ 10) with highly selective exclusion criteria compared to others,
and used spectacle mounted LEDs rather than a light box, likely
increasing ‘dose’ of light reaching the circadian photoreceptors
(including this study increased heterogeneity, c2 ¼ 16.67 (d.f. ¼ 9),
p ¼ 0.054, I2 ¼ 46.0%)
The pooled effect was signiﬁcant, and in the direction intended
(earlier sleep timing). Sensitivity analysis removing the extreme
outlier reduced the effect size slightly (0.34 to 0.32), but it
remained statistically signiﬁcant (p ¼ 0.015) (Fig. 2). This effect size
can be translated to 25 min earlier sleep timing (using the pooled
SD to convert overall SMD back into hours/minutes, whilst
excluding SMD of the outlier in which sleep onset was 1.5 h earlier
[63]).
Sleep inertia
Only three studies reported on sleep inertia: these were in DSPD
(n¼ 2) and SADwith hypersomnia (n¼ 1). The summary effect was
small and non-signiﬁcant.
Self-reported daytime sleepiness
Only studies in DSPD reported daytime sleepiness (n ¼ 4), all
interventions supplemented morning or pre-awakening light. Ef-
fects were heterogeneous (c2 ¼ 5.38 (d.f. ¼ 3), p ¼ 0.142,
Table 2
Characteristics of included studies, grouped by diagnosis.
Author(s) & Year N¼ Design Population
(+sleep
disturbance)
Age mean
(SD)/
(range)
Setting Country Intervention(s)
* dark highlight text ¼ light
reduction component
Light timing
selection
Intensity Spectral properties/
light source
Length
(days)
Control condition
Campbell et al.,
1993 [54]
16 controlled ASPD 70.4 (4.85) at home UK  evening light box
 watch TV during
via bio-marker 4000 lux white 12 dim light box
Figueiro et al., 2015
[55]
8 crossover ASPD 70 (4.5) at home USA  blue ﬂashing light mask in
early sleep
via bio-marker not stated blue LEDs 480 nm 7 red ﬂashing light mask
640 nm
Lack et al., 2005
[56]
25 controlled ASPD 51.2
(36e68)
Outpatient Australia  evening, 4hrs
Whilst watching TV in the lab
Set time 2500 lux White 2 <100 lux red light
Palmer et al., 2003
[57]
47 controlled ASPD (60e86) at home USA  evening light box 2.5hrs via sleep-
timing
265 lux white ﬂuorescent 28 dim light box (2 lux)
Ando et al., 1999
[58]
10 controlled DSPD 33.5 (10.7) at home USA  dawn simulation light mask via sleep-
timing
500 lux not stated 12 0.1 lux
Cole et al., 2002
[59]
54 RCT DSPD 25 (6) at home USA  bright-dawn simulation
mask
 advance sleep timing
 avoid naps
 avoid evening light
via sleep-
timing
2700 lux white 26 dim red light mask
Geerdink et al.,
2016 [60]
39 RCT, quasi-
random
DSPD 22.0 (6.3) at home Netherlands  morning blue light pulses
 advance sleep timing
 avoid light at night
via sleep-
timing
2306
melanopic lux
blue (460 nm,
80 nm)
9 amber light, avoid light at
night,
advance sleep schedule
Gradisar et al., 2011
[51]
40 RCT DSPD 14.6 (1.0) at home/
outpatient
Australia  light box on awakening
 advance wake time 30 min
day
 CBT-i
via sleep-
timing
1000 lux broad-spectrum/
outdoors
56 wait list control
Lack et al., 2007
[61]
18 RCT DSPD 28.2 (10.6) at home Australia  morning blue light via
spectacle mounted LEDs
via sleep-
timing
65 mW/cm2 470 nm (blue) 7 unclear if no treatment or
red light
Lack et al., 2007b
[62]
16 RCT DSPD 29 (18e56) at home Australia  light box on awakening
 advance wake time
via sleep-
timing
2500 lux incandescent
tungsten
7 dim light
Langevin et al.,
2014 [63]
10 RCT DSPD 16.3
(15e18)
at home Canada  morning blue light via
spectacle mounted LEDs
 eliminate light after 9pm
via sleep-
timing
2000 lux 400 < X < 750 nm 22 orange light of same
brightness
Saxvig et al., 2014
[49,64]
40 RCT DSPD 20.7 (3.1) at home Norway  morning light box
 placebo melatonin
 advance rise time 1hr each
day
via sleep-
timing
10,000lux not stated 14 morning dim red light,
placebo melatonin, advance
rise time
 morning light box
 melatonin
 advance rise time 1hr each
day
via sleep-
timing
10,000lux not stated
 morning light box
 melatonin
 advance rise time (re-
randomised for 2nd phase)
via sleep-
timing
10,000lux not stated no treatment
Avery et al., 1998
[58]
11 RCT SAD 33.0 (10.0) at home USA  dawn simulation lamp
 darken bedroom, block out
light, turn off nightlights
 avoid daylight before 8am
 avoid direct sunlight in the
daytime (sunglasses)
set time 250 lux white 7 red dawn, 1.5hr, 2 lux
Avery et al., 2002
[65]
50 controlled SAD 37.3 (6.1) at home USA  dawn simulation lamp
 wake at 6:00am
 darken bedroom
 avoid morning light before
8am
set time 250 lux white 7 dim red dawn
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Bogen et al., 2016
[43,66]
57 RCT Depression 15.4 (1.6) inpatient Germany  morning light box via MEQ 10,000lux white 14 dim light (100e150 lux)
Esaki et al., 2017
[67]
20 RCT Depression
(+sleep)
41.6 (7.3) at home Japan  amber glasses 8pm til bed,
remove only once in the dark
set time n/a n/a 14 clear glasses
Kragh et al., 2017
[44,68]
64 RCT Depression 38.4 (12) inpatient Denmark  morning light box
 wake therapy (total sleep
deprivation), in a lighted area
via MEQ 10000 lux white 63 TAU (medication, exercise,
talking therapies)
Lieverse et al., 2011
[69]
89 RCT Depression 69 (6.6) at home Netherlands  morning light box
 adherence monitoring via
wearable device
preference 7500 lux pale blue 21 red light (50 lux)
McEnany et al.,
2005 [70]
29 RCT Depression 37.5 (27
e46)
55.9 (45
e76)
at home USA  light visor 1hr on awakening via sleep-
timing
2500 lux krypton
incandescent
26 light blocking glasses for
1hr before bed
Barbini et al., 2005
[41]
32 controlled Other MH e
bipolar mania
38.2 (8.8) inpatient Italy  enforced darkness 6pm-8am
 quiet - noise deadened
 staff supervision
set time n/a n/a 3 TAU, drug therapy alone
Bromundt et al.,
2013 [71]
14 crossover Other MH e
borderline
personality
disorder
30.1 (6.0) at home Switzerland  morning light box
 rising by 9am
preference 8000 lux not stated 21 TAU, waitlist control
Henriksen et al.,
2016 [42]
19 RCT Other MH e
bipolar mania
36.0 (17.3) inpatient Norway  amber glasses 6pm till bed,
and before 8am
set time n/a n/a 7 clear glasses
Sheaves et al., 2018
[40,72]
40 RCT Other MH e
mixed acute
inpatients
(+sleep)
40 (13) inpatient UK  morning light box/natural
light
 adapted CBT-i
 dark in evening and at night
 activity tracking wearable for
motivation and feedback
via MEQ 10,000lux/
outdoors
light box/outdoor
light
14 TAU
Sit et al., 2017 [73] 46 RCT Other MH e
bipolar
depression
44.7 (14.5) at home USA  mid-day light box; titrated
from 15min to 60min per day
 adherence monitoring via
machine
set time 7,000lux 4,000 K white
ﬂuorescent
42 red light box (50 lux)
Ancoli-Israel et al.,
2002 [74]
34 RCT Dementia 85.7 (7.3) nursing
home
USA  am light box
 staff supervision
set time 2,500 lux cool-white 18 dim light, less than 50 lux,
red light
 pm light box
 staff supervision
set time 2,500 lux cool-white
Burns et al., 2009
[75,76]
46 RCT Dementia
(+sleep)
83.6 (7.9) nursing
homes
UK  am light box
 staff supervision
set time 10000 lux full spectrum 14 100 lux standard
ﬂuorescent light
Connell et al., 2007
[77]
20 RCT Dementia 79.7 (8.3) nursing
home
USA  daytime natural light
 group outdoor activity:
social, horticultural, creative,
singing
 facilitated by nurse
convenience natural light outdoor light 14 indoors, similar activities
Dowling et al., 2005
[78,79]
70 RCT
(crossover
in phase 2)
Dementia
(+sleep)
84 [10] long-term
care
USA  morning outdoor/indoor
light
 light boxes to supplement
when required
set time ~2,500 lux not stated 70 indoor light (150e200lux)
usual activities
 afternoon outdoor/indoor
light
 light boxes to supplement
when required
set time ~2,500 lux not stated
 am or pm outdoor/indoor
light
 light boxes to supplement
when required (am/pm
groups merged after
crossover in phase 2)
set time ~2,500 lux not stated
(continued on next page)
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Table 2 (continued )
Author(s) & Year N¼ Design Population
(+sleep
disturbance)
Age mean
(SD)/
(range)
Setting Country Intervention(s)
* dark highlight text ¼ light
reduction component
Light timing
selection
Intensity Spectral properties/
light source
Length
(days)
Control condition
Dowling et al., 2008
[50]
50 RCT Dementia
(+sleep)
86 (10) long-term
care
USA  morning outdoor/indoor
light
 light boxes when required
 melatonin
set time 2,500 lux not stated 70 usual activities
placebo melatonin
 morning outdoor/indoor
light
 light boxes when required
 placebo melatonin
set time 2,500 lux not stated
Fontana Gasio et al.,
2003 [80]
13 RCT Dementia
(+sleep)
86.8 (4.5) inpatient Switzerland  environmental dawn-dusk
simulation, set to
participants sleep timing
via sleep-
timing
<400 lux halogen with
diffuser
21 dawn-dusk simulation
using 15w red bulb
Friedman et al.,
2012 [45]
54 RCT Dementia 77.9 (8.1) at home USA  morning light box
 read or watch TV, during
 sleep hygiene info
 compliance aid and
explanation
via sleep-
timing
~4,200lux full spectrum 14 dim red light (ﬁlter added
to same light)
Lyketsos et al., 1999
[81]
15 RCT
crossover
Dementia 80.8 (8.7) residential
care
USA  morning bright light box
 staff supervision
convenience 10,000lux full spectrum 28 dim blinking light
McCurry et al., 2005
[46]
36 RCT Dementia
(+sleep)
77.8 (8.1) at home USA  evening natural light/light
box
 sleep hygiene
 regularise sleep times
 reduce naps
 daily walking (30min)
 reduce light at night
convenience 2,500 lux ﬂuorescent 28 dementia education and
carer support
McCurry et al., 2011
[47]
70 RCT Dementia
(+sleep)
82.2 (8.5) at home USA  evening light box
 sleep hygiene leaﬂet
 reduce light at night
convenience 2,500 lux full spectrum 56 sleep hygiene leaﬂet
 evening light box
 natural light
 walking (30 min)
 sleep hygiene leaﬂet
 reduce light at night
convenience natural light full spectrum
Mishima et al., 1998
[82]
22 RCT
crossover
Dementia
(+sleep)
81 & 78 inpatient Japan  light box 9e11am
 carer supervision
set time 5000e8000 lux full spectrum 14 dim light (300 lux)
Nowak et al., 2008
[83,84]
20 RCT Dementia 85.9 (6.24) nursing
home
USA  blue green light cap visor set time 12,000lux blue-green 14 dim red light cap visor
Ouslander et al.,
2006 [85]
173 cluster
crossover
study
Dementia 83.2 (9.0) nursing
home
USA  evening light box 2hrs
 activity and exercise
 avoid naps
 regularise sleep times
 reduce noise and continence
related disruptions at night
convenience 1,467lux full spectrum 17 TAU/waitlist control
Sloane et al., 2007
[86]
60 cluster
crossover
Dementia <65 ¼ 6
65e79¼ 28
>80 ¼ 32
long-term
care
USA  indoor light 7am-11am set time ~2500 lux not stated 21 standard indoor light
(~>500 lux) indoor light 4pm-8pm set time ~2500 lux not stated
 all day indoor light 7am-8pm set time ~2500 lux not stated
Sloane et al., 2015
[48]
17 RCT
crossover
Dementia 65e79 ¼ 6
>80 ¼ 11
at home USA  all day indoor artiﬁcial light preference 13,000 K blue white/470 nm 42 daytime 2700 K (yellow-
white) lamps & red light
box
Van Someren et al.,
1999 [87,88]
22 repeated
measures
crossover
Dementia 79 (9.4) long-term
care
Netherlands  day time indoor artiﬁcial
light
convenience 790e2190lux not stated 28 TAU
*N¼ number of participants included inmeta-analyses, RCT¼ randomised controlled trial, n/a¼ not applicable, TAU¼ treatment as usual, MH¼mental health conditions, ASPD¼ advanced sleep phase disorder, DSPD¼ delayed
sleep phase disorder, SAD ¼ seasonal affective disorder, CBT-i ¼ cognitive behavioural therapy for insomnia.
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(after its removal, c2 ¼ 1.40, (d.f. ¼ 2), p ¼ 0.496, I2 ¼ 0.0%). The
effect was non-signiﬁcant (ES ¼ 0.34, p ¼ 0.092).
Sleep onset latency (SOL)
Six studies reported SOL. Samples were community based. Age
varied and depression samples were older than DSPD samples.
Most interventions were similar, giving 30e60 min light box in the
morning. Esaki et al. (2017) instead reduced evening blue light
exposure using amber glasses [67]. Gradisar et al. (2011) included
CBT-i and light [51], and Saxvig et al. (2014) gavemelatonin in some
groups [49]. Effects were heterogeneous (c2 ¼ 15.51 (d.f. ¼ 7),
p ¼ 0.030, I2 ¼ 54.9%).
The pooled effect was signiﬁcant (p ¼ 0.033), with ES -0.27;
equivalent to 5.5 min shorter SOL. Signiﬁcance was altered by
sensitivity analysis excluding assumed (not diagnosed) DSPD
(p ¼ 0.078) (see Table S21). Sub-group analysis suggested larger
effects in DSPD (ES ¼ 0.46, p ¼ 0.006), than in depression
(ES ¼ 0.01, p ¼ 0.946).
Sleep quality
Self-reported sleep quality (visual analogue scale; VAS) was
measured in DSPD and depression. Most samples were young. Most
interventions weremorning or pre-awakening light, some included
nighttime light avoidance. One intervention instead used amber
glasses in the evenings [67].
Effects were heterogeneous, even within diagnostic groups
(c2 ¼ 12.62 (d.f. ¼ 6) p ¼ 0.049, I2 ¼ 52.5%). Heterogeneity was
reduced by removing the same outlier [63] (c2 ¼ 5.50 (d.f. ¼ 5)
p ¼ 0.358, I2 ¼ 9.0%). The pooled ES of 0.28 toward improved sleep
quality was statistically signiﬁcant (p ¼ 0.046), but was altered by
sensitivity analyses (ES 0.18 to 0.38, p ¼ 0.013 to 0.266). The ES of
0.28 translates to 0.25 points improvement on a 5-point Likert scale
(using the pooled SD to convert overall SMD back to VAS).
Self-reported sleep disturbance (composite measures)
Composite measures of self-reported sleep disturbance (e.g.,
insomnia severity index (ISI)) were used in DSPD, inpatient mental
illness, and bipolar depression (inpatients). Most interventions
gave early morning bright light (>2500 lux), except Sit et al. (2017)
gave early afternoon bright light [73]. Saxvig et al. (2014) added
melatonin in some groups [49], and Sheaves et al. (2018) also gave
CBT-i [89]. Effects were homogeneous (c2 ¼ 5.15 (d.f. ¼ 6),
p ¼ 0.525, I2 ¼ 0.0%).
The pooled effect was an ES of 0.32 (lower sleep disturbance)
(p¼ 0.015) (Fig. 3), which was robust to all sensitivity analyses, and
can be translated to a 1.26 points reduction in ISI score.
Total sleep time (TST)
TST was measured in most studies. Results were heterogeneous
across diagnostic groups (c2 ¼ 68.21 (d.f. ¼ 33), p ¼ 0.000,
I2 ¼ 51.6%), and within all groups except dementia (c2 ¼ 4.34,
p ¼ 0.996, I-squared ¼ 0.0%) and depression (c2 ¼ 0.89, p ¼ 0.642,
I2 ¼ 0.0%). The populations with largest ES were most heteroge-
neous. Heterogeneity remained after removal of two extreme
positive outliers [41,63]. There was a small ES of 0.15 toward longer
sleep (p ¼ 0.015) (Fig. 4). Sensitivity analyses removing positive
outliers reduced signiﬁcance (p ¼ 0.097), and as did removing
studies in samples without sleep disturbance inclusion criteria
(perhaps counterintuitively) (p ¼ 0.209). Removing studies at high
risk of bias increased the ES (¼0.20) and signiﬁcance (p ¼ 0.002).Additional post hoc sensitivity analysis excluding studies with
longer average TSTs at baseline had minimal effect on results
(adequate examination of the impact of baseline TST would require
individual patient data).Sleep efﬁciency (SE%)
All diagnostic groupings except ‘other mental health conditions’
measured SE%. Effect sizes were relatively homogenous despite
clinical heterogeneity in intervention and population characteris-
tics (c2 ¼ 18.98 (d.f. ¼ 18) p ¼ 0.393, I2 ¼ 5.1%). The pooled effect
was small and non-signiﬁcant (ES ¼ 0.14, p ¼ 0.063). Sensitivity
analyses affected the overall result slightly as statistical signiﬁcance
varied (ES ¼ 0.10 to 0.15, p ¼ 0.045 to 0.330).Sleep continuity disruption
Sleep continuity disruption was measured in many diagnostic
groups. Light intensity and duration varied, one study used amber
glasses [42]. Results were heterogenous between groups, whilst
within the dementia sub-group results were homogeneous
(c2 ¼ 10.59 (d.f. ¼ 17) p ¼ 0.877, I2 ¼ 0.0%).
The pooled ES of 0.23 was highly statistically signiﬁcant
(p ¼ 0.000) (reduced sleep disruption), this translated to 6.1 min
less wake time after sleep onset, or 1.44 less awakenings per night
(using pooled SD to convert back from SMD). ES varied signiﬁcantly
between diagnostic groups (see section below), with larger ES in
mental illness and ASPD (1.45, 0.75 and 0.50), and homoge-
neous, small, non-signiﬁcant effects in dementia (ES ¼ 0.12,
p ¼ 0.089) (Fig. 5). Sensitivity analyses made little difference to
results (ES ¼ 0.20 to 0.27, p ¼ <0.000 to p ¼ 0.038).Rhythmicity of rest activity rhythm
Rhythmicity was only measured in dementia. Light adminis-
tration, timing, intensity and duration varied; none reduced light as
the primary intervention. Rhythmicity was always derived from
actigraphy, but algorithms varied including non-parametric and
parametric approaches (extended cosine model). Results were
reasonably homogenous (c2 ¼ 9.54 (d.f. ¼ 9), p ¼ 0.389, I2 ¼ 5.6%).
The pooled effect was non-signiﬁcant (p ¼ 0.585) and close to the
line of no effect (ES ¼ 0.06).Amplitude of rest activity rhythm
Amplitude was only measured in dementia. Metrics varied;
relative amplitude was most common, but other metrics such as
percentage of activity in night-time were also reported. Results
were not signiﬁcantly heterogeneous (c2 ¼ 16.94 (d.f. ¼ 15)
p ¼ 0.323, I2 ¼ 11.4%), nor was the effect signiﬁcant (ES ¼ 0.03,
p ¼ 0.644).Carer reported daytime sleep propensity
Self-reported sleepiness was not available for samples with
dementia, so carer reported daytime sleep propensity was
examined (assessed through behavioural observations suggest-
ing sleepiness or nodding off). Heterogeneity was low
(c2 ¼ 15.01 (d.f. ¼ 13) p ¼ 0.307, I2 ¼ 13.4%) and the pooled
effect non-signiﬁcant (ES ¼ 0.13, p ¼ 0.096) despite the large
number of comparisons (n ¼ 13) and participants (438/299)
included.
Table 3
Effect of interventions altering light exposure patterns on sleep outcomes.
Outcome Included Effect Heterogeneity
Ns Nc n (Ix/Cx) Direction of effect with Ix SMD (g) 95% CI p¼ I2% p¼
Sleep timing in ASPD 4 4 52/52 Earlier (undesirable) (n.s) 0.15 0.54; 0.23 0.439 0.0 0.602
Sleep timing in DSPD 8 10 137/118 Earlier (desirable) 0.34 0.60, 0.08 0.010 46.0 0.054
Sleep inertia 3 3 74/69 Less sleep inertia (n.s) 0.26 0.59, 0.08 0.132 37.9 0.200
Self-reported daytime sleepiness 4 4 55/49 Less daytime sleepiness (n.s) 0.34 0.74, 0.06 0.092 44.2 0.146
Sleep onset latency (SOL) 6 8 138/131 Shorter SOL ¡0.27 0.52, 0.02 0.033 54.9 0.030
Sleep quality (on VAS) 5 7 113/107 Higher sleep quality 0.28 0.00, 0.55 0.046 52.5 0.049
Self-reported sleep disturbance (questionnaire) 5 7 119/116 Less sleep disturbance ¡0.32 0.58, 0.06 0.015 0.0 0.525
Total sleep time (TST) 27 34 703/492 Longer TST 0.15 0.03, 0.27 0.015 57.6 0.000
Sleep Efﬁciency (SE%) 15 19 427/364 Higher SE% (n.s) 0.14 0.01, 0.28 0.063 5.1 0.393
Sleep continuity disruption 20 24 672/509 Less sleep disruption ¡0.23 0.36, 0.10 0.000 30.9 0.125
Rhythmicity of rest activity rhythm 6 10 252/123 Lower rhythmicity (n.s.) 0.06 0.28, 0.16 0.585 5.6 0.389
Amplitude of rest activity rhythm 11 16 463/314 Higher amplitude (n.s) 0.03 0.11, 0.18 0.644 11.4 0.323
Carer reported daytime sleep propensity 10 14 439/299 Less daytime sleepiness (n.s) 0.13 0.28, 0.02 0.096 13.4 0.307
Ns¼ number of studies, Nc¼ number of comparisons, n (Ix/Cx)¼ number of participants in combined intervention and control groups, n.s.¼ not signiﬁcant, ASPD¼ advanced
sleep phase disorder, DSPD ¼ delayed sleep phase disorder. Bold text ¼ statistically signiﬁcant effect on outcome.
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Few studies presented data for follow-up points. Studies varied
in terms of inclusion of maintenance therapy or advice, and many
ceased intervention completely, so these results could not be
synthesised.
Differences between outcomes depending on population
Results for sub-groups are presented in Table 4. CIs for out-
comes overlapped substantially in all cases except TST and sleep
continuity. The overall test for heterogeneity between sub-groups
was likely to be invalid due to within group heterogeneity. Where
CIs did not overlap, or only just overlapped, we tested for dif-
ferences between subgroups using the method described in
Bornstein et al. (2009), and found no statistically signiﬁcant
differences.
Intervention effect moderators
There were too few studies to run meta-regressions for some
outcomes, and sometimes planned covariates varied insufﬁciently
or were too confounded with other features. InsufﬁcientFig. 2. Effect of morning light interventions on sleep timing in DSPD.reporting of season prevented meaningful examination of latitude
or season (without season, latitude does not describe baseline
light environment). Features related to intervention ‘dose’ (in-
tensity, duration) were mostly well reported, and varied, allowing
meta-regression; but we found no signiﬁcant associations be-
tween ‘dose’ features and effects (see Table S22). Spectral
composition of light, or bulb type was reported too infrequently
to permit analysis (see supplement S1). Variability in effects
based on intervention type (e.g., light box, natural light, light
restriction) was examined using sub-group analysis, results are
presented in supplements S23e34. Due to small numbers and
many confounders further interpretation was resisted. Pm light
exposure (versus am) was associated with a greater reduction in
carer reported daytime sleep propensity in dementia
(Coefﬁcient ¼ e0.5007139, p ¼ 0.019). Interventions with a sleep
schedule component were also associated with less deterioration
of rest activity rhythm amplitude in dementia
(Coefﬁcient ¼ 0.4587271, p ¼ 0.010).
The strongest association was between interventions including
light avoidance/reduction, and greater increase in TST
(Coefﬁcient ¼ 0.6477418, p ¼ 0.004). The association was greatest
when light was avoided not just at night but from afternoon or
evening (Coefﬁcient ¼ 1.48552, p ¼ 0.000) (Fig. 6). On other out-
comes, interventions including light avoidance also performedFig. 3. Effect of light schedule interventions on self-reported sleep disturbance.
Fig. 4. Effect of light schedule intervention on total sleep time (TST).
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differences in effects on TST were population related, meta-
regressions were re-run excluding groups where no interventionsFig. 5. Effect of light schedule interventiinvolved light reduction; associations remained highly signiﬁcant
(Coefﬁcient ¼ 0.6944778, p ¼ 0.006, and, Coefﬁcient ¼ 1.69882,
p ¼ 0.009).ons on sleep continuity disruption.
Table 4
Intervention effects in diagnostic sub-groups.
Outcome (only listing those relevant and with data) Studies reporting/total studies SMD (g) 95% CI p¼
ASPD Sleep timing 4/4 0.15a 0.54, 0.23 0.439
TST 3/4 0.05a 0.47, 0.38 0.823
SE% 3/4 0.02a 0.47, 0.43 0.929
Sleep continuity disruption 3/4 0.50 0.93, 0.07 0.023
Rhythmicity of rest activity 0/4
DSPD Sleep timing 8/8 0.34 0.60, 0.08 0.010
Sleep inertia 2/8 0.04 0.45, 0.37 0.845
Self-reported daytime sleepiness 4/8 0.34 0.74, 0.06 0.092
SOL 4/8 0.46 0.79, 0.13 0.006
Sleep quality (on VAS) 3/8 0.21 0.13, 0.55 0.217
Self-reported sleep disturbance 4/8 0.29 0.61, 0.04 0.087
TST 6/8 0.31 0.03, 0.65 0.070
SE% 2/8 0.07a 0.47, 0.32 0.720
Rhythmicity of rest activity 0/4
Depression SOL 2/5 0.01 0.39, 0.36 0.946
Sleep quality (on VAS) 2/5 0.39 0.07, 0.84 0.094
TST 3/5 0.20 0.09, 0.49 0.174
SE% 2/5 0.27 0.09, 0.64 0.139
Sleep continuity disruption 3/5 0.75 1.17, 0.32 0.001
SAD with hypersomnia Sleep inertia 1/2 0.68 1.28, 0.11 0.02
TST 1/2 0.38a 0.83, 1.58 0.541
Other mental health conditions Self-reported sleep disturbance 2/4 0.39 0.82, 0.04 0.078
TST 2/4 0.71 0.21, 1.21 0.005
Sleep continuity disruption 1/4 1.45 2.50, 0.40 0.007
Dementia TST 10/16 0.06 0.10, 0.22 0.460
SE% 7/16 0.17 0.01, 0.36 0.066
Sleep continuity disruption 14/16 0.12 0.27, 0.02 0.089
Rhythmicity of rest activity 6/16 0.06a 0.28, 0.16 0.585
Amplitude of rest activity rhythm 11/16 0.03 0.11, 0.18 0.644
Carer report daytime sleep propensity 6/16 0.13 0.28, 0.02 0.096
TST¼ total sleep time, SE%¼ sleep efﬁciency percentage, SOL¼ sleep onset latency, VAS¼ visual analogue scale, DSPD¼ delayed sleep phase disorder, ASPD¼ advanced sleep
phase disorder.
a Opposite direction to desired effect.
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Summary of ﬁndings
We found studies of light schedule interventions to improve
sleep in a range of populations, but there were relatively few studies
in samples with mental illnesses which targeted and measured
sleep and circadian disturbances. This despite the fact that circadian
dysregulation is acknowledged to be important in this group [36].
Many studies inmental illness were excluded because they reported
no sleep outcomes, and when present sleep outcomes were usuallyFig. 6. Bubble plot - light avoidance from afternoon or evening associated with greater
increase in total sleep time.secondary. Interventions predominantly involved a circumscribed
period of light exposure, most commonly from a light box at a set
time each day. Some interventions were more complex and
included modiﬁcations to both morning and evening light levels,
personalisation of light schedules, or light from multiple sources.
Overall, the effects of light schedule interventions on sleep
outcomes were positive. We found evidence of small but statisti-
cally and clinically signiﬁcant improvements in sleep continuity
disruption, self-reported sleep disturbance, and sleep timing in
DSPD, that were robust to sensitivity analyses. We found less
conclusive evidence of improvements in SE%, SOL, and self-
reported sleep quality; and a small increase in TST. These ﬁndings
are broadly in agreement with previous meta-analytic ﬁndings
where different sleep outcome types were pooled, and where study
inclusion required diagnosis or speciﬁcation of sleep problems at
baseline [30]. The current review contributes a synthesis of evi-
dence in psychiatric diagnoses, and separate analysis of various
sleep and rest-activity outcomes.Effects in sleep phase disorders
Basic research has found reasonably consistent effects of light
interventions on circadian phase, the direction and magnitude of
which depend on timing, intensity, spectral properties, and
duration of light exposure [90e92]. Our ﬁndings conﬁrm that the
phase advancing effects of morning light established in laboratory
settings can be replicated to some degree in the home in DSPD.
This ﬁnding builds on previous syntheses in DSPD where reported
effects were also positive but less conclusive [29]. We found a
shortening of SOL, and an average advance in sleep timing of
25 min, suggesting morning light intervention may be sufﬁcient
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intervention. Basic research suggests that increasing morning
light for phase advance, or evening light for phase delay, should be
more effective if light is also avoided during the opposite period
(morning/evening) [93]. Whilst across all studies those including
light avoidance gave greater increase in TST, we were not able to
deﬁnitely establish superiority of effects for adding evening light
avoidance to morning light exposure from the studies in DSPD.
Our ﬁndings did not support increased evening light exposure to
phase delay sleep in ASPD, and no studies in ASPD included
morning light avoidance, but the total number of participants in
this analysis was small.
Effects on sleep continuity and sleep disturbance
Light exposure interventions improved sleep continuity, self-
reported sleep disturbance, and sleep quality (although the latter
was affected by removing an outlier, and by removing studies
without sleep inclusion in sensitivity analysis). This is consistent
with ﬁndings in shift work: attempts to sleep out of phase with
circadian rhythm are understood to incur increased disruptions
[94], whilst increasing circadian alignment can improve sleep
quality [95]. Sleep continuity should be considered as a potential
outcome in more studies, because it is important to patients [13],
has been linked to next-day symptoms [96], may be amenable to
change, and can be assessed with actigraphy or self-report.
Effect on total sleep time (TST)
Themost commonly reported parameter was TST (27/40 studies).
Our primary analysis showed a small average effect toward longer
sleep (ES¼ 0.15, p¼ 0.015). This effect size is similar to the effect sizes
found by VanMaanen et al. (2016) (effect of light therapy on ‘all sleep
problems’ and ‘other sleep problems’). Changes to mean TST are
difﬁcult to interpret without individual patient data, or sub-grouping
by baseline sleep duration. Inmany diagnostic groups, an individual's
sleepmay be short, long, or already of normal (optimal) duration but
poor quality, thus the desirable direction of change varies. Chiu et al.
(2018) stratiﬁed participantswith schizophrenia and other psychoses
by sleep duration at baseline (<6hrs, 6e10hrs,>10hrs) and found that
intervention with CBT-i (compared to control condition) increased
TST in thosewith short sleep and reducedTST in thosewith long sleep
(both desirable), the mean value however obscured both effects. We
recommend that studies of light schedule interventions consider
stratifying participants by baseline TST, and that a future review on
this topic might examine this outcome using individual patient data.
Effect on sleep efﬁciency (SE%)
Another commonly reported but difﬁcult-to-interpret metric is
SE%; SE% is inﬂuenced by SOL, sleep fragmentation, and unwanted
early awakening. Inconsistencies in how SE% is calculated are
common, and persist despite efforts at standardisation [97,98].
Furthermore, although higher SE% is an accepted intervention
target in insomnia studies, it is not clear if very high SE% (>90%)
should always be viewed positively. Very high SE% (mean 96.6%)
was found to be a feature of sub-type “insomniawith hypersomnia”
in people with psychotic illnesses, who had excessively long sleep
and a subjective complaint of sleeping poorly [21].
Baseline light exposure patterns as an effect moderator
We hypothesised that if baseline light exposure patterns were
already close to optimal, that alterations during intervention may
make less of a difference. We were not able to examine this due tosparse reporting. Future studies should report season or months of
intervention in order that future syntheses may examine whether
season and latitude moderate intervention effects. Some studies in
institutions examined baseline light levels in the environment, but
none examined individuals' dynamic light exposure at baseline. It is
possible that variability of baseline light exposure accounts for
some heterogeneity of effects.
The signal received from daily light exposure patterns can be
described as high or low amplitude; high amplitude being bright
days and dark nights, and low amplitude being quite similar light
levels throughout. The modern light environment for many in-
dividuals involves rather dimly lit days spent indoors, artiﬁcially
elongated days with artiﬁcial light in the evening, and darkness
only when it is time to sleep. Modelling describes how this low
amplitude signal with evening light, delays and de-stabilises
circadian rhythms [99]. By contrast reverting to a more natural
light-dark signal was found to improve circadian rhythms and sleep
[2]. This research suggests that normalising light schedules by
reducing artiﬁcial evening light would improve sleep, our ﬁndings
agree with this, and suggest interventions were more effective if
they included evening light avoidance/reduction.
Studies in dementia compared to in other populations
There were distinct differences in approaches to intervention and
outcome selection between studies in dementia and in other con-
ditions. For instance, studies in dementia almost always used actig-
raphy, were more likely to specify some sleep disturbance inclusion
criteria, and often set sleep as a higher priority amongst their stated
aims. Only studies in dementia modiﬁed the living environment to
alter overall daytime light levels, and more often used natural light,
or light from a range of sources. Despite more studies focussing on
sleep, intervention effects in dementia were notably smaller and less
signiﬁcant than in other groups (and similar to in a previous meta-
analysis [28]). Caution is advised interpreting sub-group analyses
of differences in treatment effects based on sample characteristics
[38]; associations are observational and other factors may explain
differences. The use of parametric circadian analysis may have
contributed to poor measurement, as non-parametric methods have
since been shown to detect change better [88]. It is also possible that
interventions were insufﬁciently personalised, as interventions were
commonly applied to whole institutions.
Studies in mental illness
Although twelve studies in mental illness were included, each
only contributed a small amount of data, reporting few sleep out-
comes, usually with sleep as a secondary aim. Sleep outcomes are
often neglected in mental health intervention research; for
instance studies in bipolar disorder seldom measure sleep, despite
these interventions often containing components targeting sleep
[100]. Though it was not our aim to compare effects between
diagnostic groups, some of the largest effects were seen in mental
illness samples (such as sleep continuity disruption in depression,
ES ¼ 0.75, TST in other mental health conditions, ES ¼ 0.71). This
suggests that light schedule interventions which have previously
focused primarily on affective symptoms might consider also tar-
geting and measuring sleep outcomes.
Research links a more regular diurnal rhythm to better mental
wellbeing and functioning [11]. A regular rhythm is also described
as important by people with mental health conditions, in order to
support social integration, functioning, and wellbeing [13,101,102].
We had therefore identiﬁed regularity of rhythm as a relevant
outcome in these groups, and planned to examine effects on reg-
ularity and amplitude, but these metrics were only reported in
Research agenda
 Studies in psychiatric populations should consider tar-
geting sleep outcomes, as findings are promising but
research is sparse.
 Studies should consider altering light-dark exposure
patterns over the whole day or during multiple periods.
 There should be mores studies of evening light avoid-
ance/reduction.
 Controlled studies aiming to phase advance or phase
delay sleep timing should compare the effects of using
timed light exposure and timed light avoidance, with
‘single component’ light exposure or light avoidance.
 In groups where sleep and circadian rhythm problems are
diverse, samples should be stratified by type of sleep
problem, particularly where the desired effects differ (e.g.,
delayed versus advanced sleep, short versus long sleep).
 Studies should report season of intervention delivery;
and may consider examining individual participant's
baseline light exposure patterns.
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mental illness measure rest-activity timing and rhythm, as well as
sleep quality and amount.
Co-morbid circadian dysregulation
Relatively few studies in mental illness were included despite
broadening criteria to capture more studies. Without broadening
criteria only 4/12 studies in mental illness, and 7/16 in dementia
would have been included, as only these speciﬁed sleep inclusion
criteria. Interpretation of the current review is therefore contingent
on the assumption that sleep problems are prevalent enough in the
included neuropsychiatric populations that sleep disruption
criteria would not have changed the samples too greatly. Although
sensitivity analyses found no consistent or marked difference be-
tween studies with or without sleep inclusion criteria, the rele-
vance of studies without them can of course be questioned, and
there may be a difference in effect which we were unable to detect.
Furthermore, sleep problems in our included neuropsychiatric
samples would most likely also have had non-circadian causes:
anxiety and arousal processes of insomnia, environmental in-
terruptions, and the impact of affective or psychotic symptoms.
Better assessment and description of the different types and causes
of sleep disturbance in populations with neuropsychiatric disorders
would allow more targeted intervention using the most relevant
components. Although more reporting of secondary sleep out-
comes in mental health interventions is welcome the ﬁeld needs
more intervention trials targeting speciﬁc types of sleep distur-
bance and circadian dysregulation as primary outcomes.
Conclusions
This review highlights promising initial ﬁndings regarding the
effects of altering patterns of light exposure on sleep in groups
experiencing, or potentially experiencing, circadian dysregulation.
This is despite some intervention protocols not appearing to be
optimised according to current theoretical understanding, and
despite only a few studies selecting participants speciﬁcally for
presence of relevant sleep and circadian problems. Our ﬁndings
suggest that small but clinically meaningful improvements in some
sleep parameters can be achieved through altering light exposure
patterns in some groups. To achieve greater effects, light exposure
interventions may be further optimised and better targeted to
particular types of sleep and circadian problems, and appropriately
combined with other behavioural elements.Practice points
 Our findings support the use of morning light exposure to
advance sleep timing and hasten sleep onset in delayed
sleep phase disorder; average effects are small so in
many cases other intervention components may be
required in addition.
 Interventions altering light exposure may be helpful for
improving sleep continuity or sleep disturbance in groups
with circadian dysregulation; appropriate light schedule
alterations will depend upon the group.
 Enhancing evening darkness to promote sleep may be
useful; evidence is as yet weak but side effects are few (as
long as risk of falls is mitigated).Author's contributions
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